Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (May 2018)
29 slides from Painchek's investor presentation, May 17, 2018
Slide 1: Investor Presentation Update
For personal use only Investor Presentation Update May 2018 PainChek Ltd 1
Slide 2: Highlights
Highlights For personal use only • A digital healthcare company • First to global market mobile app to assess and monitor pain – pain the most common reason to see a doctor – accurate pain assessment is a big problem • Very large global market opportunities • Multiple products and revenue channels •
Slide 3: Our Why
Our Why For personal use only Our purpose is to give a voice to people who cannot verbalise their pain 3
Slide 4: Our Target Markets
Our Target Markets For personal use only Carers of non-communicative people Nannies, with pain: BabysittersD ay Care Staff Doctors Children, Parents ▪ Dementia sufferers & Grandparents ▪ Pre-verbal children Nurses Day Care Centres Carers of people who cannot self- GP, Outpatient, report their First
Slide 5: The pain problem in dementia care
The pain problem in dementia care For personal use only ▪ Up to 85% of people in aged care suffer pain regularly1 ▪ More than 50% of people in Australian aged care have dementia2 ▪ Pain is often poorly assessed, documented, monitored and managed ▪ Tools are subjective and manually based ▪ Adverse im
Slide 6: Evolution of Pain Assessments in Dementia
Evolution of Pain Assessments in Dementia For personal use only PainChek™ 2003 2017 • 2002 2004 AGS
Slide 7: The PainChek solution
The PainChekTM solution For personal use only • A secure, validated, medical device in the form of a mobile app • Uses existing smartphone and tablet hardware • Artificial Intelligence (AI) technology to analyze facial expressions indicative of pain in real time 8
Slide 8: PainChek: Software as a Medical Device
PainChek™: Software as a Medical Device For personal use only •Best Practice Tools • Automated Facial •Binary Guided Recognition Checklists • Micro-facial Pain • Clinical validation Feature analysis • POC testing Intelligent Artificial Automation Intelligence IoT and Regulatory Cloud & Clinical • Cl
Slide 9: The Team
THE TEAM For personal use only Prof. Jeff Hughes Mustafa Atee Philip Daffas Chief Scientific Officer PhD, MPS Research Scientist MPS, PhD (candidate) CEO & Managing Director, MBA, BSc Jeff is a professor in the School of Pharmacy, Mustafa is a clinical, community and academic Philip is a highly acco
Slide 10: PainChek staggered market entry strategy
PainChek™ staggered market entry strategy – current access to 40% of the global market For personal use only 1 2 3 Australia/NZ International US entry 2019/20 2017/18 Expansion 2018/19 Goal: Establish sales, business Goal: Expand into international Goal: Extend into US market post model and clinical
Slide 11: PainChek benefits impact all key decision makers
PainChek™ benefits impact all key decision makers For personal use only • Improve quality of life Clinical • Reduce rates and severity of behavioural and psychological symptoms Utility • Reduce rates of incorrectly prescribed antipsychotics • Improve staff retention • Point of Care testing Cost • Au
Slide 12: Clinical acceptance of PainChek continues to increase
Clinical acceptance of PainChek™ continues to increase For personal use only ▪ 1000 + PainChek clinical assessments in RAC setting and Dementia Support Australia ▪ PCK has the potential to become a standard in clinical care ▪ Two peer reviewed publication – with three new publications in process ▪ G
Slide 13: PainChek Case Study
PainChek™ Case Study 1 PainChek™ Case Study 2 ▪ 84 year old male ▪ 72 year old female For personal use only ▪ Referred with physical ▪ Referred with agitated aggression during care behaviour, restless at night ▪ Pain suspected to be impacting on behaviour ▪ Pain suspected to be impacting on behaviou
Slide 14: PainChek Australia Dementia App Market Strategy
PainChek™ Australia Dementia App Market Strategy Residential For personal use only Enterprise Sale: Business to Business Aged Care (RAC) 210,000 beds & Home Carers 3rd Party Operators The “not for Software (HCO) profit” RAC 200,000 Suppliers providers also packages supply the majority of Home Care P
Slide 15: PainChek can become the Universal Pain Assessment tool
PainChek™ can become the Universal Pain Assessment tool – initially within Aged Care For personal use only High 30-50% of RAC residents 60%+ of RAC New PainChek™ solutions High 10-15% of Home Care residents planned to document pain 20-30% of Home for “people who can Care verbalise” RAC 210,000 Beds
Slide 16: RAC market continues to consolidate
RAC market continues to consolidate as 1% of the Providers own 26% of the total facilities For personal use only Percentage of (RAC) market Providers Number of facilities (RACs) facilities Uniting Care Total* 185 6.9% Southern Cross Total* 88 3.3% Opal Aged Care 72 2.7% Bupa Aged Care 71 2.7% Estia
Slide 17: Residential Aged Care Market Progress
Residential Aged Care Market Progress For personal use only PainChek ™ existing business: Australia residential aged care market • 3 RAC providers with existing PainChek™ licensing agreements • 949 RAC providers • Dementia Support Australia (DSA) agreement extended into FY’19 • 2673 RACs (Residentia
Slide 18: PainChek building a cost effective Enterprise Business Model
PainChek™ building a cost effective Enterprise Business Model For personal use only Pre-Sales On-Boarding Post-Sales Support • Key Account • Portal based pain • License agreements: recurring Management assessment reports monthly subscriptions based on relationships in place • Customer #beds/resident
Slide 19: PainChek secure automated resident data exchange
PainChek™ secure automated resident data exchange For personal use only 20
Slide 20: PainChek integrates seamlessly into client patient care systems
PainChek ™ integrates seamlessly into client patient care systems For personal use only
Slide 21: PainChek Australia Dementia App Market Strategy
PainChek™ Australia Dementia App Market Strategy For personal use only Enterprise Sale: Business to Business Residential Aged Care (RAC) & Home Carers The “not for 3rd Party Operators Software profit” RAC (HCO) providers also Suppliers supply the majority of Home Care Packages 330,000 Direct to Home
Slide 22: Direct to Home Carer Opportunity
Direct to Home Carer Opportunity For personal use only • Majority of people living with Dementia live at home • Government drive towards home care included Consumer Directive Care (CDC) initiative • PainChek™ Direct to Carer App scheduled for Q3 2018 47 Million with Dementia1 • growing at 3% p.a. Ca
Slide 23: Blue sky market is pre-verbal children
Blue sky market is pre-verbal children For personal use only ▪ Neonates (0-1 month), infants and toddlers (1 month – 3 years) ▪ Sources of pain include: rashes, teething, middle ear infections, headaches, gastro-intestinal. ▪ Current pain assessments are often subjective and based on intuitions, ass
Slide 24: Children's App commercialisation Update
Children’s App commercialisation Update For personal use only ▪ Children’s video ▪ Infant App Images and regulatory library now clearance complete scheduled for Q4 2108 in Australia ▪ Prototype infants App (0-1 years) ▪ Toddlers (1-3 scheduled for years) and Clinical studies Children’s (4 and regula
Slide 25: Regulatory: Dementia App FDA de Novo clearance can act as a predicate
Regulatory: Dementia App FDA de Novo clearance can act as a predicate for the Kids App For personal use only Product development & FDA de Novo Clinical Studies (Aus) classification FDA de Novo TGA/CE Dementia App clearance as a clearance Potential additional US based clinical data Predicate device c
Slide 26: PainChek Patent Status
PainChekTM Patent Status For personal use only ▪ Patent clearance for PCT filing received in August 2016 ▪ National filings commenced Feb 2017 in all key global markets; ▪ Europe ▪ US ▪ Australia ▪ China ▪ Japan 27
Slide 27: PainChek Key Milestones
PainChekTM Key Milestones Dementia App Pre-Verbal Children Apps For personal use only Q4 2017 Q4 2017 First commercial sales achieved in Q3 & Q4 2017 Completion of children video library, data model and algorithm – on track Q1 2018 Built Australian commercial Q1-2 2018 team to execute on sales Devel
Slide 28: Financial Update
Financial Update For personal use only • Current shares on issue: 834,134,587 • Market cap undiluted at 6.2c = $52m • Market Cap fully diluted at 6.2c = $62m • Unlisted Options on issue: 175,167,730 • Fully diluted capital:1,009,302,317 • Cash at bank: 31st March 2018: $4m 29
Slide 29: Highlights
Highlights For personal use only • A digital healthcare company • First to global market mobile app to assess and monitor pain – pain the most common reason to see a doctor – accurate pain assessment is a big problem • Very large global market opportunities • Multiple products and revenue channels •